ODDO BHF raises target for Sartorius stock to EUR 335.00

Published on 10/02/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius guides to 5 to 9 percent sales growth in fiscal 2026. Sartorius stock costs EUR 252.60 on October 2, 2026 after EUR 250.85.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 252.60 at Lang & Schwarz on October 2, 2026 at 2:31 p.m. CEST, up 0.70 percent versus the prior close of EUR 250.85. According to Goldesel on October 2, 2026, ODDO BHF raised its target for Sartorius preference shares from EUR 285.00 to EUR 335.00 and kept its Outperform rating. The EUR 50.00 increase gives the latest analyst call the clearest immediate reference point for the stock.

Analysts lift the valuation bar

ODDO BHF now places its target EUR 82.40 above the Lang & Schwarz price. That gap is 24.60 percent of the target, calculated from EUR 335.00 and EUR 252.60, so the recommendation depends on continued operating progress rather than the target change alone.

The move follows another target increase. Aktiencheck reported on October 1, 2026 that Barclays lifted its target from EUR 300.00 to EUR 310.00 while maintaining Overweight. Finanznachrichten also reported on October 1, 2026 that Goldman Sachs raised its target from EUR 228.00 to EUR 244.00 but retained Neutral. The differing ratings show that the higher targets are not a uniform analyst view.

Guidance sets the next test

Sartorius guides to sales revenue growth of 5 to 9 percent in constant currencies for fiscal 2026 and expects its underlying EBITDA margin to rise above 30 percent, versus 29.7 percent in fiscal 2025. The company also identifies a 12.5 percent capital expenditure ratio for fiscal 2026, keeping investment high while the business recovers.

The next scheduled test is the third-quarter report on October 22, 2026, cited in the recent analyst coverage. For the stock, that date matters because the latest target increases are tied to expectations for clearer full-year guidance and sustained bioprocessing recovery.

Stock stays below its yearly high

Sartorius stock remains EUR 17.40 below its 52-week high of EUR 270.00 and EUR 54.10 above its 52-week low of EUR 198.50, both dated October 2, 2026. Its market capitalization was EUR 17.2 billion on that date, while the Lang & Schwarz quote stood at EUR 252.60 at 2:31 p.m. CEST, plus 0.70 percent versus EUR 250.85 on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.